What plant does umbelliprenin come from?

Umbelliprenin is isolated primarily from plants in the Ferula genus, including Ferula szowitsiana, Ferula galbaniflua, and Dorema ammoniacum, all members of the Apiaceae (carrot) family. These plants are native to the Middle East and Central Asia and have been used historically in traditional Persian medicine. The compound is concentrated in the resinous exudates and roots of these species.

What is the IC₅₀ of umbelliprenin against cancer cells?

In melanoma cell line studies, umbelliprenin demonstrated an IC₅₀ of 12.5 µM, meaning that concentration inhibited 50% of cell proliferation in vitro. This potency was associated with G₁ phase cell cycle arrest through downregulation of cyclin D1 and CDK4. IC₅₀ values vary across different cancer cell lines and experimental conditions, and these figures are derived solely from preclinical laboratory models.

Does umbelliprenin have anti-inflammatory properties?

Yes, preclinical evidence indicates umbelliprenin reduces inflammation by inhibiting COX-2 enzyme activity and suppressing NF-κB signaling, thereby lowering prostaglandin E2 production. In carrageenan-induced paw edema rodent models, oral or injected umbelliprenin produced measurable reductions in edema volume. However, no human clinical trials have confirmed these anti-inflammatory effects, so the relevance to human inflammatory conditions such as arthritis remains speculative.

Is umbelliprenin safe to take as a supplement?

There are currently no published human clinical trials evaluating the safety, dosing, or tolerability of umbelliprenin as a dietary supplement. Animal studies have not reported severe acute toxicity, but a safe and effective human dose has not been established. Until robust pharmacokinetic and safety data from human studies are available, supplementation with umbelliprenin should be approached with significant caution, particularly by pregnant individuals, those on medications, or cancer patients undergoing active treatment.

How does umbelliprenin differ from other coumarins like umbelliferone?

Umbelliprenin is a prenylated derivative of umbelliferone, meaning it has an additional geranyl (C10 prenyl) side chain attached to the coumarin core structure, which significantly enhances its lipophilicity and bioactivity compared to the parent compound umbelliferone. This prenylation is associated with greater cell membrane permeability and stronger interactions with intracellular targets such as cyclin D1, CDK4, and Bcl-2 family proteins. Umbelliferone itself shows more modest anti-inflammatory activity and lacks the demonstrated cell cycle arrest potency seen with umbelliprenin in cancer models.

What is the current evidence status for umbelliprenin in human clinical trials?

Umbelliprenin currently lacks published human clinical trials, with all efficacy data derived from preclinical studies in animal models and cell cultures. The anti-cancer activity demonstrated in mouse tumor models and the anti-inflammatory effects observed in rodent paw edema studies represent promising but preliminary findings that require human translation. Any supplement marketing umbelliprenin for health benefits is based on laboratory evidence rather than human safety or efficacy data.

Who should avoid umbelliprenin supplementation based on current evidence?

Pregnant women, nursing mothers, and individuals with coagulation disorders should avoid umbelliprenin until human safety data is available, as coumarins can affect bleeding risk and fetal development. People taking anticoagulant or antiplatelet medications should consult healthcare providers before use, as umbelliprenin's mechanism as a 5-lipoxygenase inhibitor may interact with these drugs. Children and individuals with liver disease should also avoid supplementation due to insufficient safety evidence in these populations.

How does umbelliprenin's bioavailability compare to other naturally derived coumarins?

Umbelliprenin's oral bioavailability and tissue penetration have not been formally studied in humans or animals, making direct comparisons to other coumarins impossible. As a prenylated coumarin (unlike simpler structures like umbelliferone), its lipophilic prenyl side chain may theoretically enhance cell membrane permeability, but this remains untested. Absorption kinetics, metabolism pathways, and elimination rates are completely unknown for this compound.

Umbelliprenin

Umbelliprenin is a natural coumarin-derived prenylated compound found primarily in Ferula species plants, including Ferula szowitsiana and Dorema ammoniacum. It exerts anticancer and anti-inflammatory effects primarily by inducing G₁ phase cell cycle arrest, suppressing tumor proliferation, and inhibiting pro-inflammatory mediator release.

Category: Compound Evidence: 2/10 Tier: Emerging

Origin & History

Umbelliprenin is a prenylated coumarin (7-prenoxycoumarin) with the chemical formula C₂₄H₃₀O₃, naturally occurring in various edible plants including celery, coriander, angelica, lemon, and particularly Ferula species in the Apiaceae family. This secondary plant metabolite has a molecular weight of 366.50 g/mol and requires storage at -20°C protected from light due to photochemical instability.

Historical & Cultural Context

No traditional medicinal use of umbelliprenin is documented in the available research. While the compound occurs naturally in commonly consumed plants like celery and coriander, no historical applications in traditional medicine systems are reported.

Health Benefits

• Anti-cancer activity: Demonstrated tumor reduction in mouse models, including 4T1 allograft and Lewis lung carcinoma, with cell cycle arrest at G₁ phase in melanoma cells (IC₅₀ = 12.5 µM) - evidence from preclinical studies only
• Anti-inflammatory effects: Reduced carrageenan-induced paw edema in mice at 0.01 mmol/kg and inhibited 5-lipoxygenase (IC₅₀ = 72.5 nM) - limited to animal studies
• Antiparasitic activity: Active against Leishmania major promastigotes (IC₅₀ = 13.3 µM) - in vitro evidence only
• Immunomodulatory properties: Exhibited immunostimulatory activities in tumor-bearing mice - mechanism not fully characterized
• Antioxidant activity: Displays antioxidant properties - specific pathways and human relevance not established

How It Works

Umbelliprenin induces cell cycle arrest at the G₁ phase by downregulating cyclin D1 and CDK4 expression, effectively halting tumor cell proliferation in melanoma and lung carcinoma models. It also suppresses NF-κB signaling and inhibits COX-2 enzyme activity, reducing downstream prostaglandin E2 synthesis responsible for inflammatory responses. Additionally, umbelliprenin promotes apoptosis via the intrinsic mitochondrial pathway, evidenced by increased Bax/Bcl-2 ratios and caspase-3 activation in cancer cell lines.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses are available for umbelliprenin. All current evidence is limited to preclinical in vitro and animal studies, including mouse models for cancer (4T1 allograft, Lewis lung carcinoma) and inflammation (carrageenan-induced edema).

Clinical Summary

All current evidence for umbelliprenin is preclinical, derived from in vitro cell studies and rodent models with no published human clinical trials to date. In mouse 4T1 allograft and Lewis lung carcinoma models, umbelliprenin demonstrated measurable tumor reduction, while melanoma cell studies recorded an IC₅₀ of 12.5 µM for antiproliferative activity. Anti-inflammatory efficacy was demonstrated in carrageenan-induced paw edema rodent models, showing statistically significant edema reduction comparable to reference anti-inflammatory agents in some assays. The overall evidence base is considered preliminary, and extrapolation of these findings to human therapeutic applications requires rigorous clinical validation.

Nutritional Profile

Umbelliprenin is a pure bioactive coumarin compound (specifically a prenylated coumarin/sesquiterpene coumarin), not a food ingredient, and therefore has no conventional macronutrient or micronutrient profile. Molecular formula: C₂₄H₃₀O₃, molecular weight: 382.49 g/mol. It is classified as a natural furanocoumarin derivative isolated primarily from plants of the Apiaceae/Umbelliferae family (e.g., Ferula species including Ferula galbaniflua, Ferula szowitsiana, and Dorema ammoniacum). As a pure phytochemical compound: Protein content = 0g, Carbohydrates = 0g, Fats = 0g, Fiber = 0g, Calories = negligible/not applicable. Bioactive compound concentration in source plants: Umbelliprenin constitutes approximately 0.1–2% of dried Ferula species resin by weight depending on extraction method and plant part. The compound is highly lipophilic (logP estimated ~4.5–5.5), suggesting poor aqueous solubility and limited oral bioavailability in its native form. Bioavailability notes: Absorption is expected to be limited by low water solubility; nanoparticle formulations and liposomal encapsulation have been explored in research settings to improve bioavailability. No dietary reference intakes (DRIs) or established safe dosage ranges exist for human consumption. All pharmacological data derives from in vitro and animal model studies at defined molar concentrations (e.g., IC₅₀ = 12.5 µM in melanoma cell lines; 0.01 mmol/kg in murine anti-inflammatory models).

Preparation & Dosage

No clinically studied dosage ranges for human use have been established. The only documented dose is from animal studies where 0.01 mmol/kg reduced inflammation in mice. No standardized extract dosages or human dosing recommendations are available. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Auraptene, quercetin, curcumin, resveratrol, green tea extract

Safety & Interactions

No human safety or toxicology trials for umbelliprenin have been published, making a definitive side effect profile impossible to establish at this time. Animal studies have not consistently reported acute toxicity at tested doses, but the therapeutic window in humans remains entirely unknown. Theoretical drug interactions exist with anticoagulants, chemotherapy agents, and COX inhibitors such as NSAIDs or aspirin, given umbelliprenin's overlapping anti-inflammatory and cell-signaling mechanisms. Pregnant or breastfeeding individuals and those on oncology treatment protocols should avoid umbelliprenin supplementation until human safety data are available.